Latest filings (excl ownership)
8-K
Inhibrx Reports First Quarter 2024 Financial Results
9 May 24
10-Q
2024 Q1
Quarterly report
9 May 24
8-K
Other Events
8 May 24
DEFM14A
Proxy related to merger
26 Apr 24
DEFA14A
Additional proxy soliciting materials
12 Mar 24
8-K
Other Events
12 Mar 24
8-K
Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results
28 Feb 24
10-K
2023 FY
Annual report
28 Feb 24
DEFA14A
Additional proxy soliciting materials
6 Feb 24
DEFA14A
Additional proxy soliciting materials
23 Jan 24
DEFA14A
Additional proxy soliciting materials
23 Jan 24
8-K
Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B
23 Jan 24
8-K
Inhibrx Reports Third Quarter 2023 Financial Results
9 Nov 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma
2 Nov 23
8-K
Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada
19 Sep 23
D
$200.00 mm in equity / options / securities to be acquired, sold $200.00 mm, 5 investors
31 Aug 23
8-K
Inhibrx Announces $200 Million Private Placement Financing
29 Aug 23
8-K
Inhibrx Reports Second Quarter 2023 Financial Results
7 Aug 23
10-Q
2023 Q2
Quarterly report
7 Aug 23
8-K
Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency
30 May 23
8-K
Submission of Matters to a Vote of Security Holders
25 May 23
8-K
Inhibrx Reports First Quarter 2023 Financial Results
8 May 23
10-Q
2023 Q1
Quarterly report
8 May 23
8-K
Inhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD and Announces Lift of Partial Clinical Hold on INBRX-109 DR5 Agonist Trials
26 Apr 23
DEFA14A
Additional proxy soliciting materials
13 Apr 23
DEF 14A
Definitive proxy
13 Apr 23
8-K
Regulation FD Disclosure
10 Mar 23
S-8
Registration of securities for employees
6 Mar 23
8-K
Inhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial Results
6 Mar 23
10-K
2022 FY
Annual report
6 Mar 23
8-K
Regulation FD Disclosure
16 Nov 22
8-K
Inhibrx Reports Third Quarter 2022 Financial Results
7 Nov 22
10-Q
2022 Q3
Quarterly report
7 Nov 22
8-K
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
26 Oct 22
UPLOAD
Letter from SEC
5 Oct 22
8-K
Entry into a Material Definitive Agreement
4 Oct 22
CORRESP
Correspondence with SEC
23 Sep 22
UPLOAD
Letter from SEC
15 Sep 22
8-K
European Medicines Agency Grants Orphan Drug Designation to INBRX-109 for the Treatment of Chondrosarcoma
15 Aug 22
Latest ownership filings
4
Kelly Deck
8 May 24
144
Notice of proposed sale of securities
6 May 24
4
Kelly Deck
28 Mar 24
144
Notice of proposed sale of securities
26 Mar 24
4
Kelly Deck
22 Mar 24
144
Notice of proposed sale of securities
22 Mar 24
144
Notice of proposed sale of securities
21 Mar 24
144
Notice of proposed sale of securities
20 Mar 24
4
Brendan P. Eckelman
15 Mar 24
4
Kelly Deck
15 Mar 24
144
Notice of proposed sale of securities
13 Mar 24
144
Notice of proposed sale of securities
13 Mar 24
4
Brendan P. Eckelman
12 Mar 24
4
Kelly Deck
12 Mar 24
144
Notice of proposed sale of securities
12 Mar 24
144
Notice of proposed sale of securities
11 Mar 24
144
Notice of proposed sale of securities
8 Mar 24
144
Notice of proposed sale of securities
8 Mar 24
4
Kelly Deck
6 Mar 24
144
Notice of proposed sale of securities
5 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
SC 13G/A
Kayyem Jon Faiz
14 Feb 24
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 24
SC 13G/A
PERCEPTIVE ADVISORS LLC
14 Feb 24
SC 13G/A
Lappe Mark
14 Feb 24
SC 13G/A
Eckelman Brendan P.
14 Feb 24
SC 13G/A
VIKING GLOBAL INVESTORS LP
14 Feb 24
SC 13G/A
BlackRock Inc.
29 Jan 24
SC 13G/A
STATE STREET CORP
23 Jan 24
4
OLE ANDREAS HALVORSEN
30 Aug 23
4
DOUGLAS FORSYTH
30 May 23
4
Kristiina MD Vuori
30 May 23
4
KIMBERLY MANHARD
30 May 23
4
Jon Faiz Kayyem
30 May 23
SC 13G/A
Inhibrx / Inhibrx ownership change
9 Mar 23
SC 13G/A
Inhibrx / Inhibrx ownership change
9 Mar 23
SC 13G/A
Inhibrx / Inhibrx ownership change
9 Mar 23
4
Brendan P. Eckelman
2 Mar 23
4
Mark Lappe
1 Mar 23
SC 13G/A
PERCEPTIVE ADVISORS LLC
14 Feb 23